Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06691243 · ClinicalTrials.gov registry record · Phase 2

Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

A Phase 2 study of HIV and Cocaine Use Disorder, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
2
Study locations

NCT06691243: Recruiting Phase 2 study of HIV and Cocaine Use Disorder, sponsored by University of Maryland, Baltimore.

NCT06691243 is a Phase 2 study of HIV and Cocaine Use Disorder that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 40 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06691243, a Phase 2 study of HIV and Cocaine Use Disorder, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Primary Outcome

Number of Grade 3 and 4 adverse effects reported by patients at any time after Day 0

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Semaglutide

Study Locations (2)

District of Columbia

  • Institute of Human Virology at the University of Maryland School of Medicine - Washington D.C.

Maryland

  • Institute of Human Virology at the University of Maryland School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-07
Est. Completion 2027-03
Phase Phase 2
University of Maryland, Baltimore

560 total trials

What NCT06691243 shows while recruiting

NCT06691243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06691243 reports a single indexed study location in District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06691243 about?

NCT06691243 is a clinical study titled "Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV". The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of...

What is the current status of trial NCT06691243?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-07. Estimated completion is 2027-03.

What conditions does trial NCT06691243 study?

This clinical trial studies the following conditions: HIV, Cocaine Use Disorder.

What interventions are being tested in trial NCT06691243?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).

Who is sponsoring clinical trial NCT06691243?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06691243 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06691243's enrollment target sits among peer trials

40 243rd of 303 higher than 58 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06691243, the US trial registry maintained by the National Library of Medicine. NCT06691243 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.